Share
Services
Worldwide
Fresenius and the Städel Museum have been working together since 2024 to make art accessible to a wider audience and demonstrate their commitment to the region. They are now extending their partnership for a further two years.
Worldwide
For a long time, lung cancer was only discovered when it was almost too late for those affected. A new lung cancer screening program is now helping to change the situation – giving millions of people a real chance of early diagnosis and treatment.
Germany
Helios Hospital Berlin-Buch is one of the first hospitals in Germany to use augmented reality in the operating room.
Germany
Our Sustainability Advisory Board got together for the first meeting of this year at Fresenius Kabi’s production and logistics site in Friedberg.
Worldwide
They serve patients beyond expectations and always give their best – not just in the fight against cancer, but also when striving for the highest possible quality of life.
Worldwide
With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.
Worldwide
Antimicrobial resistance (AMR) is a growing global threat. Fresenius is stepping up, through responsible manufacturing, hospital hygiene, and targeted antibiotic use, to help ensure these life-saving medicines remain effective.
Worldwide
A little medical miracle at the Helios hospital in Pforzheim
Worldwide
How Fresenius Kabi is using immersive simulations to deepen understanding of chronic illness.
Worldwide
This year marks a major milestone in our company’s history: the 50th anniversary of Fresubin®. What began as a clinical solution in 1975 has grown into a trusted and comprehensive enteral nutrition product brand for patients around the world.
Worldwide
Doctors are already setting new standards in the early diagnosis of disease with the robot-assisted “Ion endoluminal system” for bronchoscopy.
Deutschland
#FutureFresenius is making the company fit for the future. And the brand identity must reflect and support this.
Worldwide
Fresenius highlights its commitment to delivering excellent patient care and advancing medical innovation. One patient’s story shows how we bring hope and compassion when it matters most.
Worldwide
How Quirónsalud explores the impact of images on our well-being and the implications for new approaches in patient care
Worldwide
On today’s World Cancer Day, Fresenius highlights what individualized cancer care means in practice. One patient’s story shows why seeing the whole person behind the diagnosis matters across the entire patient journey.
Worldwide
Advances in medicine can save lives – but only when they reach patients. On today’s World Health Day, explore how Fresenius’ businesses bring research & development, new technology, and care together to help improve outcomes for patients.
Worldwide
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
Worldwide
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
Germany
Professor Dr. Michael Untch from Helios Hospital Berlin-Buch explains how the new antibody-drug conjugates (ADCs) are changing the fight against cancer.
USA
Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.
Germany
How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.
Europe
By supporting the renowned museum foundation, the healthcare company demonstrates its social responsibility. The partnership is at the same time a clear commitment to Frankfurt and the Rhine-Main region.
Germany
Read our interview to find out what Dr. Anna Ossami Saidy, a doctor in training at the Helios Clinic Berlin-Buch, is currently researching.
Germany
How artificial intelligence helps to detect polyps that can’t be seen by the human eye
Germany
“Personalized tumor medicine can be more effective at fighting tumors and produce beneficial therapies with fewer side effects.”
Germany
Get to know more about how this year started for Michael Sen, his view on trends like AI in health care and health equity.
Germany
Hendrik Otto and Verena Kaiser from Helios explain the benefits of changing your diet
Europe
Quirónsalud focuses on digitalisation to improve oncology patient care
Germany
Interview with Prof. Iwasaki, winner of the Else Kröner Fresenius Prize for Medical Research 2023, endowed with 2.5 million euros.
Germany
Anesthetic gas recycling reduces greenhouse gas emissions by 90 percent
Latin America
Fresenius Kabi Employees in the Dominican Republic are working to create a healthier environment.
Europe
Dr. Veronika Wolter is the first deaf person in Germany to achieve the position of chief physician. She herself uses a hearing prosthesis, and understands her patients very well.
Europe
Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Europe
How two brave adventurers from Switzerland are exploring the world step-by-step.
Europe
As a leading global healthcare group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
Fresenius has entered into a strategic development agreement with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next generation treatments.
Under the agreement, operating company Fresenius Kabi receives an exclusive license to integrate TQ Therapeutics’ proprietary cell selection technology into its Cue® Cell Processing System. The combined solution aims to isolate high purity T cells in less than two hours, helping therapy developers streamline processes and accelerate development.
The collaboration is in line with Fresenius’ #FutureFresenius strategy to focus on high value healthcare platforms, strengthen core technologies, and improve patient access through operational excellence and innovation.
By enabling more automated, robust, and scalable cell therapy manufacturing, Fresenius Kabi and TQ Therapeutics aim to support the broader adoption of cell and gene therapies, including applications closer to the point of care.
January 19, 2026
Frankfurt, Germany
January 19 – 20, 2026
The sale of the Austrian project business and spa operations of VAMED Vitality World to PORR, announced by Fresenius in October 2025, has received the necessary approvals and will be completed on December 31, 2025.
December 15, 2025 - 01:00 pm CET
Virtual
Members of the Fresenius and Fresenius Kabi management team provided insights into the Biopharma business.
Please use the link below to watch the replay of the webcast.
The virtual Biopharma ‘Meet the Management’ event took place on December 15, 2025 at 01:00 pm CET.
Members of the Fresenius and Fresenius Kabi management team provided insights into the Biopharma business.
Please use the link below to watch the replay of the webcast.
Our Fresenius Capital Markets Day 2024 took place on June 5, 2024 in London.
During the event, we presented and discussed Fresenius Helios’ role as Operating Company within #FutureFresenius, elaborated on its strategy in more detail and provided in-depth information on Fresenius Helios’ operating businesses and growth prospects.
Presenters were Michael Sen, CEO of Fresenius, and Robert Möller, CEO of Fresenius Helios, and his management team.
A recording of the Capital Markets Day is available below in various languages.
The Fresenius Capital Markets Day took place in London on May 25, 2023, in a hybrid format. A replay of the webcast is available.
As part of the event, we presented and discussed Fresenius Kabi’s role as Operating Company within #FutureFresenius, elaborated on its “Vision 2026” in more detail and provided in-depth information on the company’s operating businesses and growth prospects.
Presenters were Michael Sen, CEO of Fresenius, and Pierluigi Antonelli, CEO of Fresenius Kabi, and his management team.
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Biopharma ‚Meet the Management‘ Presentation
January 12, 2026
San Francisco, USA
January 12 – 14, 2026
